Impact of the COVID-19 pandemic on cancer screening in Europe: A systematic review of disruptions, barriers, and policy responses [0.03%]
欧洲新冠肺炎疫情对癌症筛查的影响：中断、障碍及政策响应的系统综述
Zeyu Wang,Bohua Ren,Salman Rawaf et al.
Zeyu Wang et al.
Background: Cancer screening is a cornerstone of cancer control, but the COVID-19 pandemic caused unprecedented disruption to preventive healthcare worldwide. In Europe, national screening programmes were severely affecte...
Clinical role of breast ultrasound surveillance in detecting locoregional recurrences after bilateral mastectomies [0.03%]
双侧乳房切除术后乳腺超声监测在检测局部区域复发方面的临床作用
Meng-Yuan Tsai,Ping-Chun Tai,Sheng-Wen Wang et al.
Meng-Yuan Tsai et al.
Purpose: This study evaluates the effectiveness of breast ultrasound in detecting locoregional recurrences specifically after bilateral mastectomies, a population underrepresented in existing surveillance guidelines. ...
Factors predictive of progression in lesions categorised as well-differentiated papillary mesothelial tumour of the pleura, tunica vaginalis and peritoneum: a scoping review [0.03%]
一类浆液膜壁瘤（良性或潜在恶性肿瘤）病变进展的预测因素：系统综述
Sarita Prabhakaran,Harry James Gaffney,Yazad Irani et al.
Sarita Prabhakaran et al.
Purpose: This scoping review examines the literature on factors predictive of progression of well-differentiated papillary mesothelial tumours (WDPMT) to identify features relevant to their prognosis. ...
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer [0.03%]
生物标志物分析预测免疫检查点抑制剂治疗EGFR突变非小细胞肺癌患者疗效的研究
Koichi Azuma,Mitsuo Osuga,Shoichi Itoh et al.
Koichi Azuma et al.
Background: Immune checkpoint inhibitors (ICIs) are effective for NSCLC, but patients with NSCLC and EGFR mutations are less likely to benefit from ICI treatment. A small subset of patients harboring EGFR mutations is rep...
Long-term results of postoperative whole-breast irradiation plus simultaneous integrated boost (SIB) for adolescents and young adults (AYA) diagnosed with early breast cancer after undergoing breast-conserving surgery in a single institute [0.03%]
单中心保乳术后年轻乳腺癌患者的全乳放疗+同期增强放疗(SIB)的长期结果分析
Yi-Ting Hwang,Hui-Ling Yeh
Yi-Ting Hwang
Background/objectives: The treatment of early-stage breast cancer in adolescent and young adult (AYA) women (≤40 years old) is challenging due to aggressive disease biology and concerns about long-term toxicity. This stu...
Determinants of delayed postoperative radiation therapy in breast cancer patients undergoing neoadjuvant chemotherapy: A subanalysis of the AMAZONA III prospective cohort [0.03%]
新辅助化疗乳腺癌患者的术后放疗延迟的影响因素：AMAZONAⅢ前瞻性队列的亚组分析
Júlio César Prestes,Gustavo Viani,Andre Guimaraes Gouveia et al.
Júlio César Prestes et al.
Background: Delays in starting postoperative radiation therapy (PORT) in breast cancer patients may be associated with poorer clinical outcomes. This analysis aimed to identify factors contributing to delayed PORT in pati...
Synergistic cytotoxic effect of doxorubicin and bortezomib on lung cancer cell lines using 2D and 3D models [0.03%]
基于二维和三维模型的多西他赛和硼替佐米联合抗肺癌细胞系效应研究
Mohammad Alwahsh,Osama H Abusara,Alia Abu Zaid et al.
Mohammad Alwahsh et al.
Lung cancer is the most prevalent cause of cancer-related mortality globally. Anti-cancer monotherapy outcomes have proven insufficient to meet the clinical needs for treating lung cancer; therefore, combination therapy has been employed to...
Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors [0.03%]
FDA批准的芳香化酶抑制剂治疗ER阳性乳腺癌
Nayoung Kim,Kiven Erique Lukong
Nayoung Kim
Breast cancer is a leading cause of death among women globally. Estrogen receptor (ER)-positive breast cancers account for ∼70 % of breast cancer diagnoses worldwide. Endocrine therapy is the primary treatment approach for ER-positive brea...
Treatment and outcomes of patients with HR+/HER2- early breast cancer in a real-world setting in Germany [0.03%]
德国真实世界中HR+/HER2-早期乳腺癌患者的治疗和结局
Klaus-Ulrich Däßler,Volker Petersen,Mark-Oliver Zahn et al.
Klaus-Ulrich Däßler et al.
Background: A subset of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer (HR+/HER2- EBC) are at higher risk of disease recurrence. ...
Surviving the siege: A review on the metabolic hallmarks of cancer dormancy [0.03%]
surviving围攻：癌症休眠代谢标志的综述.review on the metabolic hallmarks of cancer dormancy
Farah Djelti,Mostefa Hani,Yazid Chetbani et al.
Farah Djelti et al.
Cancer dormancy, a period of cellular hibernation, enables malignant cells to evade treatment and later initiate metastatic relapses, representing a central challenge in oncology. This review synthesizes the evidence that defines metabolic ...